Cellcept (Mycophenolate mofetil): New risk of anaphylactic reaction identified from post-marketing data

A Dear Healthcare Professional Letter has been issued by Roche Singapore Pte Ltd to update healthcare professionals that cases of anaphylaxis, anaphylactic reaction, anaphylactic shock and anaphylactoid reaction were identified from the post-marketing data for Cellcept. Healthcare professionals are advised to be aware of the full range of signs and symptoms of anaphylactic reaction and the appropriate medical treatment. It is recommended to advise patients to seek immediate medical attention at the first signs of an anaphylactic reaction and discontinue Cellcept permanently. Roche will be updating the product label of Cellcept to reflect this newly identified risk. Please refer to the letter for details.
Healthcare professional, Industry member, Therapeutic Products
Published:

Dear Healthcare Professional Letters

11 Jul 2025

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under 'For Healthcare Professionals’.

Step 2: Click on 'Restricted Content' and log in via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’.

Step 4: Click on the Drug Alert tab to view the DHCPLs.